I suppose that the title uses "French scientists" because it sounds exotic. However this is well known, the adjuvant is nowaday the most active part of a vacci

I suppose that the title uses "French scientists" because it sounds exotic. However this is well known, the adjuvant is nowaday the most active part of a vaccine. It is by carefully crafting the adjuvant that a company could make its products sligtly better than those of their competition. I cite [0]: 'The inflammatory or danger-signal model of adjuvant action implies that increased vaccine reactogenicity is the inevitable price for improved immunogenicity. Hence, adjuvant reactogenicity may be avoidable only if it is possible to separate inflammation from adjuvant action. The biggest remaining challenge in the adjuvant field is to decipher the potential relationship between adjuvants and rare vaccine adverse reactions such as narcolepsy, macrophagic myofasciitis or Alzheimer’s disease. While existing adjuvants based on aluminum salts have a strong safety record, there is an ongoing need for new adjuvants and for more intensive research into adjuvants and their effects.' [0] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4615573/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4615573/